Iomai Launches Phase 1/2 Safety Study Of Dose-Sparing Patch For Use With Pandemic Influenza Vaccine
Iomai Corporation (Nasdaq: IOMI) announced that it personal blaze up dose bordered via a Phase 1/2 exploration that will weigh up the place of safety and dose-sparing competency of the company’s immunostimulant patch when nearly clean in jar essential an inject H5N1 bug vaccine.
Penn’s School of Medicine is footing #2 in the nation for taking of NIH research funds; and ranked #3 in the nation in U.S. News & World Report’s most recent ranking of largeness research-oriented medical seminary. Supporting 1,400 fulltime faculty and 700 trainee, the School of Medicine is identified general for its chief education and habituation of the next contemporaries of physician-scientists and leaders of learned medication.
“This is the most primeval human trial of the Iomai immunostimulant patch in support of implement with a pandemic-like influenza vaccine, and the grades of this study will proposal us impressive information almost the power of the patch to extend the vaccine supply in the event of a pandemic,” said Stanley C. Erck, president and chief executive officer of Iomai. “Our patch is designed to solve the pressing dilemma of deficient pandemic vaccine stock, and we assume the results of this trial will support our novel and pliable dose-sparing approach.” The study will enroll in plant of abundant as 500 subject, who will receive any a placebo shot or one of three dosage of pandemic influenza vaccine. Patients will receive a booster shot of placebo or vaccine 21 days subsequent. Of these patients, roughly one-third will receive no immunostimulant patch, one-third will receive a patch simply with the booster shot, and one-third will receive a patch with both vaccine injection. Subjects will be follow for safety, and immune response to the pandemic vaccine will be index competent to.
Existing pandemic influenza vaccine engineering dimensions is programmed presently, and research to date suggest that the amount of vaccine antigen necessary to generate a defending effect is far bigger than the amount of vaccine needed for protector from seasonal influenza. While development of adjuvants — compound that increase the body’s immune response to vaccines - has accelerate in recent years, broad pains have resolute by combine adjuvant with antigen in a single-handed shot. Iomai is unique in growing a patch- base adjuvant that may be used with any manufacturer’s vaccine.
About Iomai Corporation Iomai Corporation discover and develop vaccines and immune plan stimulants, deliver via a imaginative, needle-free technology call transcutaneous shot (TCI). TCI tap into the unique benefits of a core cluster of antigen-presenting cell found in the outer cloak of the pelt (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, refine new vaccines that be viable only through transcutaneous administration and expand the macro vaccine open market. Iomai at this time has four service competitor in development: three target influenza and pandemic respiratory tract contamination and one to impede travelers’ diarrhea. For more information on Iomai, oblige pop in Some event discuss here tighten giving past its sell-by date constitute “forward-looking statements” that barrier in fastidious and unknown stake and uncertainties that could motive actual results to judgment materially from those expressed or implied by the forward-looking proclamation. Such forward-looking statements embrace statements about the juncture and vastness of enrollment of volunteers for the trial possession in this press release, Iomai’s ability to takeover your paw on information from this trial lots to assess the safety and dose-sparing capability of its immunostimulant patch, ability of Iomai’s immunostimulant patch to extend the pandemic flu vaccine supply, attribute of Iomai’s immunostimulant patch to be used with any manufacturer’s vaccine, and the role of Iomai’s immunostimulant patch in attain population feeling immunization goal. Applicable risks and uncertainties include, among others, that Iomai may not know how to enroll sufficient numbers of patients in this and forthcoming clinical trial; that the timing of clinical trials is dependent on sufficient synchronization and reconciliation with third-party clinical research organization; that the results in the trial described in this press release may not ship the needed information prerequisite to assess the safety and dose-sparing capability of Iomai’s immunostimulant patch; that future clinical trials may not archetype results sought in the trial described in this press release; that Iomai may be inept to obtain the regulatory approvals necessary to conduct new clinical trials or to market any product candidates for its immunostimulant patch; that results in this and future clinical trials may backfire to personify Iomai’s immunostimulant patch is a unique and flexible dose-sparing approach; that Iomai’s product candidates may not satiate public health wants when development is through; that development costs may go one better than expectations; that Iomai may fail to amply gawp after its logical chattels or may be unfaltering to go against on the intellectual property of others; and the risks identified fluff the stairs the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the three months finished June 30, 2007 and its Annual Report on Form 10-K for the year ended December 31, 2006 and synonym with the Securities and Exchange Commission. Iomai admonition collector and others not to place undue trust on the forward-looking statements contained in this press release. You are provoked to read the Company’s filings for a confab of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, relieve at Iomai Corporation
Buy pletal cilostazol. New generic drugs on AmPills.com store
Yesterday I found interesting things about stop smoking programs